These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10114721)

  • 1. Of orphans and balloons.
    McGivney WT
    Physician Exec; 1991; 17(5):41-3. PubMed ID: 10114721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ensuring adequate payment for the use of new technology.
    Kaden RJ
    Healthc Financ Manage; 1998 Feb; 52(2):46-52. PubMed ID: 10176449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the economic challenges posed by orphan drugs.
    Drummond MF; Wilson DA; Kanavos P; Ubel P; Rovira J
    Int J Technol Assess Health Care; 2007; 23(1):36-42. PubMed ID: 17234015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A changing paradigm in the study and adoption of emerging health care technologies: coverage with evidence development.
    Wallner PE; Konski A
    J Am Coll Radiol; 2008 Nov; 5(11):1125-9. PubMed ID: 18954812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From medical invention to clinical practice: the reimbursement challenge facing new device procedures and technology--part 3: payment.
    Raab GG; Parr DH
    J Am Coll Radiol; 2006 Nov; 3(11):842-50. PubMed ID: 17412183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coverage, technology assessment, and the courts.
    McGivney WT
    Physician Exec; 1991; 17(1):36-8. PubMed ID: 10110136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lucrative niches: how drugs for rare diseases became lifeline for companies.
    Anand G
    Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
    [No Abstract]   [Full Text] [Related]  

  • 8. Medicare payment for new technologies. Can the process be improved despite conflicting goals? An ECRI technology management assessment.
    J Health Care Technol; 1986; 3(1):13-32. PubMed ID: 10300959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From medical invention to clinical practice: the reimbursement challenge facing new device procedures and technology--part 1: issues in medical device assessment.
    Raab GG; Parr DH
    J Am Coll Radiol; 2006 Sep; 3(9):694-702. PubMed ID: 17412151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of cost-effectiveness analysis in health care decision-making.
    Magel JS
    Physician Exec; 1990; 16(3):31-2. PubMed ID: 10113233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating technology under changing financing arrangements.
    Luce BR
    Trustee; 1986 Aug; 39(8):15-7. PubMed ID: 10311653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study.
    Mentzakis E; Stefanowska P; Hurley J
    Health Econ Policy Law; 2011 Jul; 6(3):405-33. PubMed ID: 21205401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational: what's in a name.
    McGivney WT
    Physician Exec; 1991; 17(2):30-1. PubMed ID: 10113675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A technology anthology. Recent writings and remarks on the state of the state-of-the-art.
    Health Syst Rev; 1997; 30(2):58, 60, 62. PubMed ID: 10165993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The scientific basis for coverage decisions by third-party payers.
    Towery OB; Perry S
    JAMA; 1981 Jan; 245(1):59-61. PubMed ID: 6776306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppliers help hospitals 'sell' care to payers.
    Souhrada L
    Hospitals; 1988 Jul; 62(13):62-3. PubMed ID: 3290087
    [No Abstract]   [Full Text] [Related]  

  • 17. The impact of technology on health care cost and policy development.
    Wallner PE; Konski A
    Semin Radiat Oncol; 2008 Jul; 18(3):194-200. PubMed ID: 18513629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria.
    Coyle D; Buxton MJ; O'Brien BJ
    Health Econ; 2003 May; 12(5):421-7. PubMed ID: 12720259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dutch doctors call for EU evaluation of cost effectiveness of high cost orphan drugs.
    Sheldon T
    BMJ; 2012 Aug; 345():e5461. PubMed ID: 22890124
    [No Abstract]   [Full Text] [Related]  

  • 20. Defining experimental therapy--a third-party payer's dilemma.
    Newcomer LN
    N Engl J Med; 1990 Dec; 323(24):1702-4. PubMed ID: 2233969
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.